Ultragenyx announces approval of Crysvita® (burosumab) in Brazil for treatment of XLH
Ultragenyx announced that Brazil’s ANVISA has approved Crysvita® (burosumab) for the treatment of X-linked hypophosphatemia in adult and pediatric patients one year of age and older. Crysvita is also approved by the FDA and Health Canada for treatment of XLH in adult and pediatric patients. March 26, 2019